Cargando…

Refractive astigmatism in phaco-canaloplasty vs phaco-non-penetrating deep sclerectomy

This study aimed to assess refractive astigmatism, in phaco-canaloplasty (PC) vs phaco-non-penetrating deep sclerectomy (PDS) in a randomized, prospective study within 24 months. Patients were randomized pre-operatively, 37 underwent PC and 38 PDS. The following data was collected: BCVA, IOP, number...

Descripción completa

Detalles Bibliográficos
Autores principales: Byszewska, Anna, Rudowicz, Jacek, Lewczuk, Katarzyna, Jabłońska, Joanna, Rękas, Marek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124182/
https://www.ncbi.nlm.nih.gov/pubmed/35597794
http://dx.doi.org/10.1038/s41598-022-12451-7
_version_ 1784711690986717184
author Byszewska, Anna
Rudowicz, Jacek
Lewczuk, Katarzyna
Jabłońska, Joanna
Rękas, Marek
author_facet Byszewska, Anna
Rudowicz, Jacek
Lewczuk, Katarzyna
Jabłońska, Joanna
Rękas, Marek
author_sort Byszewska, Anna
collection PubMed
description This study aimed to assess refractive astigmatism, in phaco-canaloplasty (PC) vs phaco-non-penetrating deep sclerectomy (PDS) in a randomized, prospective study within 24 months. Patients were randomized pre-operatively, 37 underwent PC and 38 PDS. The following data was collected: BCVA, IOP, number of antiglaucoma medications, refraction with autokeratorefractometry. The assessment of astigmatism was simple arithmetic and vector analysis (calculations included cylinder with axis in form of centroids) and included double angle plots and cumulative refractive astigmatism graphs. Pre-operative mean BCVA in PC was 0.40 ± 0.43 and was comparable to BCVA in PDS 0.30 ± 0.32logMAR (P = 0.314). In the sixth month follow-up, mean BCVA showed no difference (P = 0.708) and was 0.07 ± 0.13 and 0.05 ± 0.11, respectively. However, 2 years after the intervention mean BCVA was better in PC 0.05 ± 0.12 than in PDS 0.12 ± 0.23 and it was statistically significant (P = 0.039). Mean astigmatism in PC at baseline was 1.13 ± 0.73Dcyl, at 6 months it was 1.09 ± 0.61 and at 2 years 1.17 ± 0.51. In PDS at baseline 1.35 ± 0.91 at 6 months 1.24 ± 0.86 and at 2 years 1.24 ± 0.82. There were no differences between the groups in mean astigmatism throughout the study. Centroids (mean of a cylinder with axis) in PC were pre-operatively 0.79D@172˚ ± 1.10Dcyl, at 6 months 0.75D@166˚ ± 1.01 and at 24-months 0.64D@164˚ ± 1.11 and in PDS pre-operatively 0.28D@10˚ ± 1.63D at 6 months 0.26D@11˚ ± 1.5 and at 24-months 0.47D@20˚ ± 1.43. The direction of mean astigmatism was against the rule in all analyzed time points. The mean baseline IOP in PC was 19.4 ± 5.8 mmHg and 19.7 ± 5.4 mmHg in PDS(P = 0.639). From the 6-month IOP was lower in PC, at 24-months it was 13.8 ± 3.3 mmHg in PC and 15.1 ± 2.9 mmHg in PDS(P = 0.048). In both groups preoperatively patients used median(Me) of three antiglaucoma medications(P = 0.197), at 24-months in PC mean 0.5 ± 0.9 Me = 0.0 and 1.1 ± 1.2 Me = 1.0 in PDS(P = 0.058). Both surgeries in mid-term observation are safe and effective. They do not generate vision-threatening astigmatism and do not even change the preoperative direction of mean astigmatism. Refractive astigmatism is stable throughout the observation.
format Online
Article
Text
id pubmed-9124182
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-91241822022-05-23 Refractive astigmatism in phaco-canaloplasty vs phaco-non-penetrating deep sclerectomy Byszewska, Anna Rudowicz, Jacek Lewczuk, Katarzyna Jabłońska, Joanna Rękas, Marek Sci Rep Article This study aimed to assess refractive astigmatism, in phaco-canaloplasty (PC) vs phaco-non-penetrating deep sclerectomy (PDS) in a randomized, prospective study within 24 months. Patients were randomized pre-operatively, 37 underwent PC and 38 PDS. The following data was collected: BCVA, IOP, number of antiglaucoma medications, refraction with autokeratorefractometry. The assessment of astigmatism was simple arithmetic and vector analysis (calculations included cylinder with axis in form of centroids) and included double angle plots and cumulative refractive astigmatism graphs. Pre-operative mean BCVA in PC was 0.40 ± 0.43 and was comparable to BCVA in PDS 0.30 ± 0.32logMAR (P = 0.314). In the sixth month follow-up, mean BCVA showed no difference (P = 0.708) and was 0.07 ± 0.13 and 0.05 ± 0.11, respectively. However, 2 years after the intervention mean BCVA was better in PC 0.05 ± 0.12 than in PDS 0.12 ± 0.23 and it was statistically significant (P = 0.039). Mean astigmatism in PC at baseline was 1.13 ± 0.73Dcyl, at 6 months it was 1.09 ± 0.61 and at 2 years 1.17 ± 0.51. In PDS at baseline 1.35 ± 0.91 at 6 months 1.24 ± 0.86 and at 2 years 1.24 ± 0.82. There were no differences between the groups in mean astigmatism throughout the study. Centroids (mean of a cylinder with axis) in PC were pre-operatively 0.79D@172˚ ± 1.10Dcyl, at 6 months 0.75D@166˚ ± 1.01 and at 24-months 0.64D@164˚ ± 1.11 and in PDS pre-operatively 0.28D@10˚ ± 1.63D at 6 months 0.26D@11˚ ± 1.5 and at 24-months 0.47D@20˚ ± 1.43. The direction of mean astigmatism was against the rule in all analyzed time points. The mean baseline IOP in PC was 19.4 ± 5.8 mmHg and 19.7 ± 5.4 mmHg in PDS(P = 0.639). From the 6-month IOP was lower in PC, at 24-months it was 13.8 ± 3.3 mmHg in PC and 15.1 ± 2.9 mmHg in PDS(P = 0.048). In both groups preoperatively patients used median(Me) of three antiglaucoma medications(P = 0.197), at 24-months in PC mean 0.5 ± 0.9 Me = 0.0 and 1.1 ± 1.2 Me = 1.0 in PDS(P = 0.058). Both surgeries in mid-term observation are safe and effective. They do not generate vision-threatening astigmatism and do not even change the preoperative direction of mean astigmatism. Refractive astigmatism is stable throughout the observation. Nature Publishing Group UK 2022-05-21 /pmc/articles/PMC9124182/ /pubmed/35597794 http://dx.doi.org/10.1038/s41598-022-12451-7 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Byszewska, Anna
Rudowicz, Jacek
Lewczuk, Katarzyna
Jabłońska, Joanna
Rękas, Marek
Refractive astigmatism in phaco-canaloplasty vs phaco-non-penetrating deep sclerectomy
title Refractive astigmatism in phaco-canaloplasty vs phaco-non-penetrating deep sclerectomy
title_full Refractive astigmatism in phaco-canaloplasty vs phaco-non-penetrating deep sclerectomy
title_fullStr Refractive astigmatism in phaco-canaloplasty vs phaco-non-penetrating deep sclerectomy
title_full_unstemmed Refractive astigmatism in phaco-canaloplasty vs phaco-non-penetrating deep sclerectomy
title_short Refractive astigmatism in phaco-canaloplasty vs phaco-non-penetrating deep sclerectomy
title_sort refractive astigmatism in phaco-canaloplasty vs phaco-non-penetrating deep sclerectomy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9124182/
https://www.ncbi.nlm.nih.gov/pubmed/35597794
http://dx.doi.org/10.1038/s41598-022-12451-7
work_keys_str_mv AT byszewskaanna refractiveastigmatisminphacocanaloplastyvsphacononpenetratingdeepsclerectomy
AT rudowiczjacek refractiveastigmatisminphacocanaloplastyvsphacononpenetratingdeepsclerectomy
AT lewczukkatarzyna refractiveastigmatisminphacocanaloplastyvsphacononpenetratingdeepsclerectomy
AT jabłonskajoanna refractiveastigmatisminphacocanaloplastyvsphacononpenetratingdeepsclerectomy
AT rekasmarek refractiveastigmatisminphacocanaloplastyvsphacononpenetratingdeepsclerectomy